Featured News

Earlier this month, SSCD hosted their first quarterly webinar of 2024 on “Under-Represented Populations in Celiac Disease.” During the webinar, the Celiac Disease Foundation and SSCD announced the launch of the Improving Health Equity in Celiac Disease Through Disparities Research Award.

Dr. Esen Sefik, PhD, an immunologist and an Associate Research Scientist in the Flavell Lab at Yale School of Medicine, is the recipient of the Celiac Disease Foundation–Takeda Early Career Research Award, an award designed to support promising early-career researchers working toward independent and productive research careers in celiac disease.  

A new study published in the journal Gastro Hep Advances finds that a considerable proportion of Black patients with biopsy-confirmed celiac disease had negative diagnostic blood tests. Traditionally perceived as predominantly affecting non-Hispanic White individuals, this study underscores the importance of bridging existing research gaps to better serve underrepresented populations. 

Did you know that there are gluten-free summer camps that offer fun and peace of mind for children and teens with celiac disease? Learn about a few of the options available this summer!

Using data from the Foundation’s iCureCeliac® Patient Registry, a new observational study helps explain the relationship between persistent celiac disease symptoms, gluten-free diet adherence, mental health, and quality of life.

This month's story comes from Brett Spitale, CDF's Chief of Staff, and special guest appearance from his son, Maxwell!

The Celiac Disease Foundation is delighted to be an Official Charity Partner for the 2024 Los Angeles Marathon. On March 17, six dedicated Team Gluten-Free® runners will come together to conquer 26.2 miles, all with a shared mission – raising crucial funds to advance the diagnosis, treatments, and finding a cure for celiac disease.

In our pursuit of critical federal support for celiac disease, we understand that true progress requires a multifaceted approach. While government support is invaluable, we also recognize the power of strategic collaboration with the private sector to drive the much-needed change our community deserves.

Chugai Pharmaceutical Co., Ltd. recently published encouraging results from a non-clinical study on DONQ52, an experimental medication for celiac disease. The findings show its potential to block the immune response to gluten in celiac disease without affecting the rest of the immune system.  

The Celiac Disease Foundation is proud to announce that Robert Anderson, MB, ChB, PhD, has joined the Foundation as its Principal Science & Innovation Advisor. In his new role, Dr. Anderson will draw on his extensive background to provide scientific expertise and guidance to the organization and its stakeholders.